医学
内科学
淋巴瘤
弥漫性大B细胞淋巴瘤
疾病
癌症
肿瘤科
化学免疫疗法
病理
癌症研究
化疗
放射治疗
进行性疾病
侵袭性淋巴瘤
临床试验
作者
Hervé Tilly,Franck Morschhauser,Laurie H. Sehn,Jonathan W. Friedberg,Marek Trněný,Jeff P. Sharman,Charles Herbaux,John M. Burke,Matthew Matasar,Shinya Rai,Koji Izutsu,Neha Mehta-Shah,Lucie Oberic,Adrien Chauchet,Wojciech Jurczak,Yuqin Song,Richard Greil,Larysa Mykhalska,Juan M. Bergua-Burgués,Matthew C. Cheung
标识
DOI:10.1056/nejmoa2115304
摘要
Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP. (Funded by F. Hoffmann-La Roche/Genentech; POLARIX ClinicalTrials.gov number, NCT03274492.).
科研通智能强力驱动
Strongly Powered by AbleSci AI